Calcineurin/Nuclear Factor of Activated T-Cell Pathway in Cutaneous Squamous Cell Carcinoma
Yi Wu, Feng-Juan Li, Ke Zhang and 4 more
International Journal of Dermatology and Venerology · 2019
doi:10.1097/jd9.0000000000000030 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction Cutaneous squamous cell carcinoma (CSCC), a keratinocyte-derived skin neoplasm with malignant potential,1 represents 20%–50% of skin cancers and currently has an increasing incidence in the United States.2 Ultraviolet (UV) solar radiation is the primary risk factor for the development of CSCC, and the cumulative exposure received over a lifetime plays a major role in this development.3 Mutations in the p53 gene are the most common genetic abnormalities, causing nonfunctional p53 protein production and cells with damaged DNA replicate in CSCC.4 Recent studies have shown that CSCC-free survival was shorter in the group treated with a calcineurin inhibitor compared with the group treated with sirolimus, which is a mammalian target of rapamycin (mTOR) inhibitor,5 and withdrawal of the calcineurin inhibitor reduced subsequent nonmelanoma cancers.6 Additionally, functional evidence supports a critical role for calcineurin/nuclear factor of activated T-cell (NFAT) signaling in CSCC, specifically in tumor initiation and development and in the tumor microenvironment. Herein, we discuss these findings of the calcineurin/NFAT pathway in CSCC in this review. General introduction of calcineurin/NFAT pathway Calcineurin is the only known highly conserved serine-threonine phosphatase under calcium-calmodulin control, and its activation promotes the localization of NFAT to the nucleus.7 Calcineurin consists of a catalytic subunit A (CnA) and a regulatory subunit B (CnB). The CnA contains a phosphatase catalytic domain, a CnB-binding domain, a calmodulin-binding domain, and a carboxy-terminal autoinhibitory domain. The CnB has a main latch region with four Ca2+-binding EF-hand motifs, through which calcineurin is recognized by immunosuppressive complexes and competitively binds to the CnA.8 NFAT family includes NFAT1 (NFATc2/NFATp), NFAT2 (NFATc1/NFATc), NFAT3 (NFATc4), NFAT4 (NFATc3/NFATx), and NFAT5. NFAT proteins contain an amino-terminal transactivation domain and a carboxy-terminal domain. NFAT1-4 has an additional Rel-homology region, similar to the DNA-binding domain of the nuclear factor kappa-B family, and an NFAT homology region, which is a regulatory domain with a calcineurin-binding site.8 The calcineurin/NFAT pathway is primarily activated by the increased level of intracellular Ca2+. During the resting phase, the autoinhibitory domain interacts with the calmodulin-binding domain to inhibit its phosphatase activity. In the activated state, an increased cytoplasmic Ca2+ concentration assists calmodulin in displacing the autoinhibitory domain and promotes CnB binding to CnA by activating Ca2+-binding EF-hand motifs in the CnB, which ultimately leads to calcineurin activation. The activated calcineurin dephosphorylates multiple phospho-residues in the NFAT homology region, leading to NFAT cytoplasmic–nuclear trafficking9 and the induction of NFAT-mediated gene transcription.8 The roles of calcineurin/NFAT pathway in CSCC Involvement in tumor initiation and development Cyclosporine A (CsA), which is a commonly used immunosuppressant, and function as an inhibitor of the calcineurin/NFAT pathway. Transplant recipients receive treatment with CsA and tacrolimus to prevent transplant rejection, which is accompanied by a high incidence of skin cancer, especially CSCC. Notably, other more recently developed immunosuppressive drugs that do not affect calcineurin activity, such as mTOR inhibitors, have a much lower impact on CSCC formation.6,10 Thus, although immune suppression is important, it is unlikely to directly account for the selectively increased risk of CSCC development associated with calcineurin inhibit treatments, suggesting an intrinsic role for the calcineurin/NFAT pathway in keratinocyte tumor suppression. Calcineurin/NFAT pathway has been proved to play a significant role in skin stem cells.11 Recent evidence has shown that hair follicle stem cells act as cancer cells of origin for CSCC and cannot initiate tumors during the quiescent phase of the hair cycle. Horsley et al.12 reported that NFATc1 is preferentially expressed by hair follicle stem cells in their niche, where its expression is activated by bone morphogenetic protein (BMP) signaling upstream. NFATc1 acts downstream to repress CDK4 and maintain stem cell quiescence, which can be stopped by pharmacologically suppressing calcineurin/NFATc1 signaling or via a complete or conditional NFATc1 gene ablation. NFATc1 has been reported to regulate bulge stem cell activity during native hair aging13 and pregnancy.14 A recent study found that the expression of NFAT3 was high in A431 cell lines, whereas it was markedly lower in the immortalized skin cell line HaCaT. As expected, compared with normal skin tissue, NFAT3 was highly expressed in tumor tissues. Furthermore, a knockdown of endogenous NFAT3 expression by short hairpin RNA significantly inhibited A431 cell proliferation, colony formation, and anchorage-independent cell growth.15 Antagonistic role of calcineurin and ATF3 in p53-dependent cancer cell senescence Cancer cell senescence is a failure-protected mechanism against tumor development that can inhibit the cancer stem cell potential. Genetic and pharmacological suppression of calcineurin/NFAT function increased ATF3 expression by abolishing the binding of endogenous NFATc1 to two distinct regions of the ATF3 promoter harboring NFAT-binding sites and subsequently blocked the expression of p53 and senescence-associated genes, thereby reducing senescence and promoting tumor formation in mouse skin and in xenografts.16 This process must be independent of the pathway described in Ref. [17] because the oxidative stress induced by CsA was too low to stabilize NRF2, and the UVA radiation doses that induce ATF3 expression do not interfere with NFATc1 activity. Considering the previously defined role of ATF3 in CSCC development, these findings may provide an explanation and a mechanism for the frequently observed CSCC burden on sun-exposed areas of the skin in organ transplant recipients who are treated with calcineurin inhibitors. However, the mTOR inhibitor sirolimus is able to reverse the expression of ATF3.18 Roles of calcineurin/NFAT pathway in the tumorigenic microenvironment SCID-beige mice, which are devoid of most innate immunity components that were injected with A431 cells and treated with CsA, developed much larger tumors with enhanced VEGF expression as compared with those treated with a vehicle control. Intriguingly, this trend continued with increased cell proliferation, decreased apoptosis, and reduced cell migration and invasion of the epithelial–mesenchymal transition after the cessation of CsA treatment, which may be due to increased TGF-β and TGF-β-dependent signaling.19 Later, paradoxically, another study reported that NFATc1 activation adjacent to neighboring cells without NFATc1 activation was sufficient for initiating CSCC along with a significant upregulation of c-Myc and Stat3 activation.20 Moreover, factors secreted by the NFATc1+ cells initiated the establishment of an inflammatory and promitogenic tissue environment for both NFATc1+ and NFATc1− cells to proliferate and become part of the tumor, which also affected the stem cells/progenitor cells and their niches, leading to their participation in tumor formation. These findings indicate that the activation of NFAT signaling establishes a tumorigenic microenvironment through cell and non-cell autonomous mechanisms.21 Goldstein et al.20 reported consistent data about the carcinogenic effect of the constitutive NFATc1 overexpression, but they did not detect overt alterations in skin inflammatory or cytokine gene expression during homeostasis after NFATc1 inhibition. These findings suggest that calcineurin may inhibit skin tumorigenesis through its regulation of additional NFAT isoforms or other proteins such as ATF3 or p53. Relationship between CSCC risk factors and calcineurin/NFAT pathway The main risk factors for CSCC include UV radiation, immunosuppression, and chronic scar formation. The relationship between these three factors and calcineurin/NFAT pathway is discussed in the following sections. UV radiation UV-induced DNA damage plays a key role in the initiation phase of skin cancer as a result of photochemical reactions, in which DNA bases absorb UV energy to form characteristic photonic layers, such as cyclobutane pyrimidine dimers and reactive oxygen species, producing mutagenic base damage and then leading to the activation of proto-oncogenes or the inactivation of tumor suppression genes.22 Irradiation of keratinocytes in culture with UVA-1 was reported to result in a dose-dependent decrease in calcineurin activity.23 Similarly, an increase in NFAT DNA-binding activity was found in the group with a low UVA dose (<45 kJ/m), whereas a reduction to 60% was found in the group with a higher dose (135 kJ/m) of UVA. However, another protein phosphatase 2A, closely related to calcineurin, was insensitive to inactivation by UVA-1 irradiation.24 Notably, UVB irradiation caused a decrease in the calcineurin activity in one of two fibroblast cultures but was ineffective in keratinocytes, even though UVB was demonstrated to be the most effective type of light for inducing skin cancer in animals.25 Upon UVA irradiation and reactive oxygen species formation, the nuclear factor erythroid 2-related factor 2(NRF2) protein is activated in cultured primary keratinocytes as well as in the epidermis of normal skin, which leads to binding of nuclear factor erythroid 2-related factor 2 to the two predicted antioxidant response element motifs in the ATF3 gene promoter and induces ATF3 expression.26A recent study revealed that calcineurin activity and NFATc1 in HaCaT cells may be necessary for UV-induced gasdermin-C expression,27 which can form pore channels to help inflammatory molecules such as interleukin-1(IL-1) to be actively released across cell membranes and cause tissue infla
Abstract licence: CC BY-NC-ND
References38
38 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.